LUNG - Pulmonx Corp Stock Price, Fair Value and News

9.01USD-0.04 (-0.44%)Market Closed

Market Summary

USD9.01-0.04

Market Closed

-0.44%

LUNG Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

LUNG Stock Price

View Fullscreen

LUNG RSI Chart

LUNG Valuation

Market Cap

349.7M

Price/Earnings (Trailing)

-5.95

Price/Sales (Trailing)

4.79

EV/EBITDA

-5.71

Price/Free Cashflow

-9.21

LUNG Price/Sales (Trailing)

LUNG Profitability

Operating Margin

100.00%

EBT Margin

-79.59%

Return on Equity

-53.15%

Return on Assets

-35.69%

Free Cashflow Yield

-10.85%

LUNG Fundamentals

LUNG Revenue

Revenue (TTM)

73.0M

Rev. Growth (Yr)

29.71%

Rev. Growth (Qtr)

-2.2%

LUNG Earnings

Earnings (TTM)

-58.7M

Earnings Growth (Yr)

13.31%

Earnings Growth (Qtr)

Breaking Down LUNG Revenue

Last 7 days

7.1%

Last 30 days

21.3%

Last 90 days

-37.1%

Trailing 12 Months

-27.3%

How does LUNG drawdown profile look like?

LUNG Financial Health

Current Ratio

6.95

Debt/Equity

0.29

Debt/Cashflow

-1.15

LUNG Investor Care

Shares Dilution (1Y)

2.83%

Diluted EPS (TTM)

-1.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	73.0M	0	0	0
2023	57.4M	60.7M	64.8M	68.7M
2022	50.0M	51.7M	51.9M	53.7M
2021	33.4M	41.9M	44.5M	48.4M
2020	35.4M	31.7M	33.3M	32.7M
2019	23.2M	26.3M	29.4M	32.6M
2018	0	0	0	20.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pulmonx Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	joshi mehul	acquired	-	-	125,870	chief financial officer & pao
Apr 22, 2024	rose geoffrey beran	sold	-8,868	7.49	-1,184	chief commercial officer
Mar 22, 2024	rose geoffrey beran	sold	-11,082	9.36	-1,184	chief commercial officer
Mar 15, 2024	williamson steven s.	acquired	-	-	205,286	president and ceo
Mar 01, 2024	lehman david aaron	acquired	-	-	34,500	general counsel
Mar 01, 2024	rose geoffrey beran	sold	-28,058	9.06	-3,097	chief commercial officer
Mar 01, 2024	french glendon e. iii	sold	-63,003	9.06	-6,954	president and ceo
Mar 01, 2024	rose geoffrey beran	acquired	-	-	34,500	chief commercial officer
Mar 01, 2024	lehman david aaron	acquired	-	-	69,100	general counsel
Mar 01, 2024	rose geoffrey beran	acquired	-	-	69,100	chief commercial officer

Which funds bought or sold LUNG recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-990,879	-	-%
May 16, 2024	COMERICA BANK	unchanged	-	-1,305	3,476	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.87	-143,566	321,975	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	reduced	-5.51	-51,534	113,094	0.01%
May 15, 2024	Squarepoint Ops LLC	new	-	370,587	370,587	-%
May 15, 2024	Engineers Gate Manager LP	added	72.83	85,324	417,882	0.01%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	new	-	188,079	188,079	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-93.88	-132,911	6,192	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-46.00	-1,308,240	845,748	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-14.98	-1,228,820	1,989,450	-%

Are Funds Buying or Selling LUNG?

Are funds buying LUNG calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LUNG

No. of Funds

Unveiling Pulmonx Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 29, 2024	point72 asset management, l.p.	5.0%	1,913,561	SC 13G
Feb 14, 2024	point72 asset management, l.p.	4.0%	1,546,089	SC 13G/A
Feb 13, 2024	vanguard group inc	5.39%	2,066,442	SC 13G/A
Feb 13, 2024	champlain investment partners, llc	0.00%	0	SC 13G/A
Feb 12, 2024	primecap management co/ca/	14.74%	5,646,451	SC 13G/A
Feb 12, 2024	flynn james e	0.02%	6,009	SC 13G/A
Feb 09, 2024	morgan stanley	5.4%	2,061,758	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 25, 2024	blackrock inc.	8.1%	3,117,063	SC 13G/A

Recent SEC filings of Pulmonx Corp

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 07, 2024	4	Insider Trading
May 03, 2024	10-Q	Quarterly Report
May 03, 2024	S-8	Employee Benefits Plan
May 01, 2024	8-K	Current Report
Apr 24, 2024	4	Insider Trading
Apr 22, 2024	144	Notice of Insider Sale Intent
Apr 09, 2024	3	Insider Trading
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Pulmonx Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.1M	3.7M	-71.13%	32.26%	-0.09	0.29	5.77%	8.23%

Pulmonx Corp News

Latest updates

Pulmonx Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-2.2%	18,854,000	19,278,000	17,668,000	17,194,000	14,535,000	15,425,000	13,502,000	13,950,000	10,785,000	13,708,000	13,261,000	12,203,000	9,244,000	9,830,000	10,612,000	3,673,000	8,618,000	10,347,000	9,104,000	7,366,000	5,778,000
Gross Profit	-2.2%	14,078,000	14,400,000	13,029,000	12,734,000	10,589,000	11,184,000	10,152,000	10,418,000	8,111,000	10,251,000	9,739,000	9,029,000	6,611,000	7,078,000	7,462,000	1,012,000	5,650,000	7,337,000	6,407,000	4,953,000	3,717,000
Operating Expenses	1.0%	28,614,000	28,319,500	28,205,000	29,173,000	26,989,000	25,811,000	24,083,000	24,829,000	23,779,000	22,617,000	19,501,000	21,711,000	19,105,000	16,432,000	12,810,000	12,538,000	11,754,000	-	10,020,000	-	-
S&GA Expenses	-0.1%	24,404,000	24,423,000	23,985,000	23,463,000	22,736,000	21,908,000	19,717,000	21,235,000	20,245,000	18,909,000	16,686,000	18,205,000	16,071,000	13,960,000	10,813,000	11,112,000	10,189,000	-	8,621,000	-	-
R&D Expenses	8.0%	4,210,000	3,896,500	4,220,000	5,710,000	4,253,000	3,903,000	4,366,000	3,594,000	3,534,000	3,708,000	2,815,000	3,506,000	3,034,000	2,472,000	1,997,000	1,426,000	1,565,000	-	1,399,000	-	-
EBITDA Margin	10.0%	-0.75	-0.83	-0.89	-0.95	-0.99	-1.07	-1.09	-1.01	-1.02	-0.98	-0.98	-0.87	-	-	-	-	-	-	-	-	-
Interest Expenses	-2.4%	883,000	904,500	893,000	864,000	571,000	359,000	286,000	223,000	198,000	199,000	207,000	206,000	217,000	267,000	1,103,000	912,000	899,000	-	460,000	-	-
Income Taxes	-25.9%	186,000	251,000	100,000	140,000	100,000	233,000	-	40,000	100,000	135,500	44,000	80,000	100,000	-1,000	49,000	100,000	87,000	-	89,000	-	-
Earnings Before Taxes	0.6%	-13,563,000	-13,640,000	-14,841,000	-16,055,000	-15,736,000	-14,037,000	-14,172,000	-14,600,000	-15,761,000	-12,854,000	-10,137,000	-12,882,000	-12,445,000	-9,276,000	-3,811,000	-11,855,000	-7,076,000	-	-4,246,000	-	-
EBT Margin	9.3%	-0.80	-0.88	-0.94	-0.99	-1.02	-1.09	-1.10	-1.03	-1.03	-1.00	-1.00	-0.92	-	-	-	-	-	-	-	-	-
Net Income	1.0%	-13,749,000	-13,888,000	-14,900,000	-16,195,000	-15,860,000	-14,283,000	-14,172,000	-14,640,000	-15,828,000	-13,006,000	-10,181,000	-12,962,000	-12,512,000	-9,297,000	-3,860,000	-11,911,000	-7,163,000	-4,669,000	-4,335,000	-5,571,000	-6,128,000
Net Income Margin	9.2%	-0.80	-0.89	-0.94	-1.00	-1.03	-1.10	-1.11	-1.04	-1.04	-1.01	-1.01	-0.92	-	-	-	-	-	-	-	-	-
Free Cashflow	-42.3%	-12,251,000	-8,610,000	-9,192,000	-7,910,000	-12,705,000	-9,976,000	-10,989,000	-9,889,000	-15,564,000	-11,836,000	-9,920,000	-13,389,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-7.4%	165	178	185	193	201	194	202	213	223	235	247	249	255	264	71.00	54.00
Current Assets	-1.7%	148	150	147	164	181	169	183	193	201	208	228	233	239	250	56.00	41.00
Cash Equivalents	-15.7%	70.00	84.00	95.00	102	110	102	112	122	129	149	188	199	209	232	40.00	15.00
Inventory	2.9%	17.00	17.00	16.00	16.00	16.00	15.00	16.00	19.00	18.00	16.00	15.00	13.00	12.00	11.00	9.00	6.00
Net PPE	4.7%	4.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00	3.00	2.00	1.00	1.00	1.00
Goodwill	0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	-9.0%	54.00	59.00	59.00	59.00	57.00	40.00	39.00	41.00	41.00	42.00	44.00	40.00	39.00	38.00	71.00	36.00
Current Liabilities	-8.0%	21.00	23.00	20.00	20.00	17.00	18.00	22.00	20.00	18.00	18.00	22.00	17.00	14.00	13.00	15.00	14.00
Short Term Borrowings	142.7%	5.00	2.00	0.00	0.00	0.00	0.00	5.00	3.00	1.00	0.00	-	-	-	-	-	-
Long Term Debt	-8.8%	32.00	35.00	37.00	37.00	37.00	17.00	12.00	14.00	17.00	17.00	-	-	-	-	30.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	3.00	2.00	0.00	-	-	-
LT Debt, Non Current	-100.0%	-	35.00	37.00	37.00	37.00	17.00	12.00	14.00	17.00	17.00	-	-	-	-	-	-
Shareholder's Equity	-6.6%	110	118	126	134	144	154	163	172	182	193	203	209	216	226	-	-
Retained Earnings	-3.3%	-424	-411	-397	-382	-366	-350	-336	-321	-307	-291	-278	-268	-255	-242	-233	-210
Additional Paid-In Capital	1.3%	533	527	521	514	508	503	498	493	488	483	480	476	470	467	25.00	22.00
Shares Outstanding	0.8%	39.00	39.00	38.00	38.00	38.00	38.00	37.00	37.00	37.00	37.00	36.00	36.00	-	-	-	-
Float	-	-	-	-	479	-	-	-	523	-	-	-	1,200	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-40.3%	-11,800	-8,410	-8,700	-7,856	-12,644	-9,800	-10,710	-9,590	-15,000	-10,688	-8,300	-12,728	-9,672	-7,262	-5,871	-7,651	-9,849	-	-	-
Share Based Compensation	1.3%	5,673	5,598	6,003	5,862	4,638	4,247	4,302	4,383	3,513	3,012	2,938	2,312	2,268	2,311	518	159	209	-	-	-
Cashflow From Investing	9.0%	-2,507	-2,755	987	-813	574	-727	44.00	2,080	-5,622	-29,124	-3,414	-1,186	-12,531	-693	-76.00	3,439	10,024	-	-	-
Cashflow From Financing	4982.4%	864	17.00	571	92.00	20,720	67.00	906	131	1,315	150	1,000	3,293	13.00	199,765	2,359	31,399	1,308	-	-	-
Buy Backs	-	-	-	-	-	-	27.00	-	-	-	-	-	-	26.00	-	-	-	-	-	12.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LUNG Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 18,854	$ 14,535
Cost of goods sold	4,776	3,946
Gross profit	14,078	10,589
Operating expenses
Research and development	4,210	4,253
Selling, general and administrative	24,404	22,736
Total operating expenses	28,614	26,989
Loss from operations	(14,536)	(16,400)
Interest income	1,441	1,127
Interest expense	(883)	(571)
Other income, net	415	108
Net loss before tax	(13,563)	(15,736)
Income tax expense	186	124
Net loss	(13,749)	(15,860)
Other comprehensive (loss) income
Currency translation adjustment	(549)	72
Change in unrealized (losses) gains on marketable securities	(128)	173
Total other comprehensive (loss) income	(677)	245
Comprehensive loss	$ (14,426)	$ (15,615)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.36)	$ (0.42)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.36)	$ (0.42)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	38,636,029	37,572,382
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	38,636,029	37,572,382

LUNG Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 70,158	$ 83,547
Restricted cash	236	237
Short-term marketable securities	45,973	33,555
Accounts receivable, net	10,522	12,105
Inventory	17,228	16,743
Prepaid expenses and other current assets	3,819	4,235
Total current assets	147,936	150,422
Long-term marketable securities	4,293	14,390
Long-term inventory	2,522	2,580
Property and equipment, net	4,218	4,028
Goodwill	2,333	2,333
Intangible assets, net	0	31
Right of use assets	2,705	3,406
Other long-term assets	577	591
Total assets	164,584	177,781
Current liabilities
Accounts payable	3,125	1,497
Accrued liabilities	10,071	16,234
Income taxes payable	67	93
Deferred revenue	110	104
Short-term debt	5,231	2,155
Current lease liabilities	2,690	3,074
Total current liabilities	21,294	23,157
Deferred tax liability	140	114
Long-term lease liabilities	650	1,106
Long-term debt	32,002	35,089
Total liabilities	54,086	59,466
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 38,812,175 shares issued and outstanding as of March 31, 2024 and 38,516,383 shares issued and outstanding as of December 31, 2023	39	39
Additional paid-in capital	533,406	526,797
Accumulated other comprehensive income	1,963	2,640
Accumulated deficit	(424,910)	(411,161)
Total stockholders’ equity	110,498	118,315
Total liabilities and stockholders’ equity	$ 164,584	$ 177,781

About Pulmonx Corp

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.

CEO	Mr. Glendon E. French
WEBSITE	https://pulmonx.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	269

Pulmonx Corp Frequently Asked Questions

What is the ticker symbol for Pulmonx Corp? What does LUNG stand for in stocks?

LUNG is the stock ticker symbol of Pulmonx Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pulmonx Corp (LUNG)?

As of Fri May 17 2024, market cap of Pulmonx Corp is 349.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LUNG stock?

You can check LUNG's fair value in chart for subscribers.

What is the fair value of LUNG stock?

You can check LUNG's fair value in chart for subscribers. The fair value of Pulmonx Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pulmonx Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LUNG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pulmonx Corp a good stock to buy?

The fair value guage provides a quick view whether LUNG is over valued or under valued. Whether Pulmonx Corp is cheap or expensive depends on the assumptions which impact Pulmonx Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUNG.

What is Pulmonx Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LUNG's PE ratio (Price to Earnings) is -5.95 and Price to Sales (PS) ratio is 4.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUNG PE ratio will change depending on the future growth rate expectations of investors.